Supriya Lifescience Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/z1hv16oy4d86ilerh6279s2x.pdf

Key Takeaways


Revenue Recovery & Growth Drivers

Satish Wagh: "And if we keep on telling everything you are in a country where you are in India, people immediately copy paste. So, nothing will be given as such in detail. That is the worry of the company as far as India is concerned."

Margin Structure & Cost Levers


New Product & Facility Pipeline


High-Purity Anesthetic: A Differentiated Bet

Satish Wagh: "Ma'am, you must understand this product, we don't have a competitor in India. We are cracking the China. Business is ample available because people don't want to go with China because they are non-GMP plants. So here we are not chasing for business, but the clients are chasing for their product because they need to change the source and move towards a regulated company like Supriya Lifescience."

CDMO & DSM: The Next Leg


Whey Protein & GLP-1: Optionality Bets

Saloni Wagh: "We are making progress, not as per the expectation. I think by now we should have already started the commercial supply, but we are expecting that to happen very soon. Maybe in about 1 or 2 months' time, it should happen. It is just that they are still deciding on the formulation part with their R&D."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth20%+ for FY26FY26 full year
EBITDA margin33%-35% rangeFY26 and next couple of years
INR 1,000 crore revenueOn trackBy FY27
Product launches3-4 this year; ADHD in Q3, contrast media end-Q3/early-Q4FY26
Ambernath revenue contributionStart from Q4 after Q3 capitalizationQ4 FY26
CAPEX~INR 80 crores for remaining FY26, primarily maintenance and small projectsFY26
DSM pharma uptakeCustomer validation underway4-5 months
DSM full revenue potentialINR 60-odd crores from pharma and foodFY27
Whey Protein commercial supplyStart in 1-2 monthsNear-term
Whey Protein full potentialMajority in FY27, full in FY28FY28
Anesthetic drug filingUSDMF and CEP filingEnd of November
New CDMO project announcements2 projects to be announcedUpcoming quarters
North America revenue increaseSlight increase expectedNext financial year
GLP-1 revenuePossibleNext financial year
GLP-1 business potential guidanceFrom Q4 after Ambernath capitalizationQ4 FY26
Cardiovascular advanced intermediateGood revenue visibilityQ1/Q2 next financial year

Key Metrics

MetricQ2 FY26
Revenue₹200 cr, +20% YoY and +38% QoQ
EBITDA₹73 cr, +12% YoY and +41% QoQ
EBITDA margin36%, in line with guidance
PAT₹50 cr, vs ₹46 cr in Q2 FY25
PAT margin25%
Exports share81% of Q2 FY26 revenues
Backward integration79% of Q2 FY26 revenues fully integrated
H1 FY26 revenue₹345 cr, +6% YoY
H1 FY26 EBITDA₹124 cr, -2.3% YoY
H1 FY26 PAT₹85 cr, vs ₹91 cr in H1 FY25
CAPEX (Q2 FY26)₹28 cr
CAPEX (H1 FY26)₹42 cr
Expected CAPEX for remaining FY26~₹80 cr, primarily maintenance and Ribo Block
Full-year CAPEX guidance₹80–₹90 cr
CWIP₹172.5 cr, of which ~₹150–₹155 cr for Ambernath (capitalizing in Q3)
Revenue growth guidance (FY26)~20% annual growth
EBITDA margin guidance33%–35%
Revenue target₹1,000 cr by FY27
New product launches planned (FY26)3–4 launches; 2 launched so far, ADHD and contrast media upcoming
DSM opportunity peak revenue₹60–₹70 cr
DSM expected revenue (FY26)₹25–₹30 cr
Whey Protein capacity~3,000 tons per year
Whey Protein expected volumes (first year)~1,000 tons
Cardiovascular advanced intermediate capacity1,000 tons; visibility of ~300 tons in advanced discussions
Fully backward integrated products18 products; 3 more in process, to become 21
Japanese PMDA approval for DSM projectReceived